{
  "docId": "019dd923-622c-750b-8b98-916758668d1f",
  "docSlug": "34401c2968d1",
  "documentTitle": "Dexcom, Inc. (DXCM)",
  "authorId": "54_Spruce_Point_Capital",
  "authorName": "Ben Axler",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2019-03-21 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 12,
  "pageCount": 83,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "preempt_rebuttal",
  "function": "preempt_rebuttal",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide uses historical precedent to argue that the market underestimates the impact of Abbott's product launches on Dexcom's valuation.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "comparison_table",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b98-916758668d1f/12",
  "deckHref": "/decks/019dd923-622c-750b-8b98-916758668d1f",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b98-916758668d1f.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b98-916758668d1f#slide-12",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "The forthcoming Libre 2 is at least as consequential as Abbott's past two CGMs from a competitive perspective, and could cause a more drastic move in DXCM shares.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-f5d2-7501-bd88-7e7b7d585f6c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Price Reaction: -33%",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-f5d2-7501-bd88-82f4259c01e7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.16
      },
      "kind": "paragraph",
      "text": "Abbott's Libre has dominated Dexcom's G-Series in recent head-to-head competition for market share even before the release of the Libre 2, which should close most or all of the technological gaps which remain between the Libre and G-Series. The U.S. launch of the technologically-strong, yet inexpensive Libre 2 could undermine what remains of the G-Series' competitive position. The market expects the release of the Libre 2, of course – but it also knew that Abbott was set to release new CGMs in 2017 and 2018, yet Dexcom's stock still suffered in the immediate aftermath. The forthcoming Libre 2 is at least as consequential as Abbott's past two CGMs from a competitive perspective, and could cause a more drastic move in DXCM shares.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "14bc64d7-822e-44cb-a673-7b65b55e6977",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.01,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "Source: Spruce Point Research. 1. FDA Approval of FreeStyle Libre (9/27/17). 2. FDA Approval of 14 day Libre FreeStyle Sensor (7/27/18).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "16e49b84-1c07-4896-8b12-32c106ddba0d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.84,
        "x": 0.08,
        "y": 0.44
      },
      "kind": "table",
      "text": "Event, Date, Device Features, Price Reaction (End-Of-Day Price) for three Abbott product launches.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "841ac2f0-58d8-4f73-aebf-6a01d66e5df0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.65,
        "x": 0.31,
        "y": 0.03
      },
      "kind": "title",
      "text": "Abbott's CGM FDA Approvals Have Not Been Kind To Dexcom's Stock Price",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f0d56b72-d6eb-4da4-b64f-c0fa4527eb57",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "preempt_rebuttal",
      "slug": null,
      "matchId": "73f3e4bf-2f2c-4e5c-a770-f031d588c2b7",
      "evidence": "Uses historical stock price reactions to argue against market expectations of a neutral or positive outcome for the upcoming product launch.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}